Invesco Ltd. Intellia Therapeutics, Inc. Transaction History

Invesco Ltd.

$503 Billion
Q1 2025

A detailed history of Invesco Ltd. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 171,175 shares of NTLA stock, worth $1.64 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

171,175

Previous 96,434 77.5%

Holding current value

$1.64 Million

Previous $1.12 Million 8.27%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	BUY	$7.11 - $12.8 $531,408 - $956,684	74,741 Added 77.5%	171,175 $1.22 Million
Q4 2024 Feb 13, 2025	BUY	$11.41 - $21.09 $41,954 - $77,547	3,677 Added 3.96%	96,434 $1.12 Million
Q3 2024 Nov 12, 2024	SELL	$19.72 - $27.36 $64,543 - $89,549	-3,273 Reduced 3.41%	92,757 $1.91 Million
Q2 2024 Aug 13, 2024	SELL	$20.02 - $27.22 $13,313 - $18,101	-665 Reduced 0.69%	96,030 $2.15 Million
Q1 2024 May 14, 2024	BUY	$23.82 - $32.8 $572,894 - $788,872	24,051 Added 33.11%	96,695 $2.66 Million
Q4 2023 Feb 12, 2024	BUY	$23.16 - $32.34 $156,144 - $218,036	6,742 Added 10.23%	72,644 $2.21 Million
Q3 2023 Nov 13, 2023	BUY	$31.62 - $45.78 $1,264 - $1,831	40 Added 0.06%	65,902 $2.08 Million
Q2 2023 Aug 11, 2023	SELL	$34.58 - $46.03 $230,233 - $306,467	-6,658 Reduced 9.18%	65,862 $2.69 Million
Q1 2023 May 12, 2023	SELL	$33.3 - $44.82 $11.5 Million - $15.5 Million	-345,358 Reduced 82.65%	72,520 $2.7 Million
Q4 2022 Feb 13, 2023	BUY	$33.21 - $62.69 $441,659 - $833,714	13,299 Added 3.29%	417,878 $14.6 Million
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $444,246 - $590,736	8,239 Added 2.08%	404,579 $22.6 Million
Q2 2022 Aug 15, 2022	BUY	$38.49 - $76.21 $294,794 - $583,692	7,659 Added 1.97%	396,340 $20.5 Million
Q1 2022 May 16, 2022	SELL	$58.27 - $118.99 $5.17 Million - $10.6 Million	-88,724 Reduced 18.58%	388,681 $28.2 Million
Q4 2021 Feb 14, 2022	SELL	$100.76 - $138.36 $19.5 Million - $26.8 Million	-193,791 Reduced 28.87%	477,405 $56.4 Million
Q3 2021 Nov 15, 2021	SELL	$132.37 - $176.78 $1.78 Million - $2.38 Million	-13,435 Reduced 1.96%	671,196 $90 Million
Q2 2021 Aug 17, 2021	SELL	$60.88 - $161.91 $33.3 Million - $88.6 Million	-546,933 Reduced 44.41%	684,631 $111 Million
Q1 2021 May 17, 2021	SELL	$46.59 - $83.68 $12.1 Million - $21.7 Million	-259,385 Reduced 17.4%	1,231,564 $98.8 Million
Q4 2020 Feb 16, 2021	BUY	$18.83 - $63.53 $22.1 Million - $74.6 Million	1,174,248 Added 370.77%	1,490,949 $81.1 Million
Q3 2020 Nov 16, 2020	BUY	$17.47 - $24.93 $4.7 Million - $6.71 Million	269,294 Added 568.05%	316,701 $6.3 Million
Q2 2020 Aug 14, 2020	BUY	$11.14 - $22.87 $306,182 - $628,581	27,485 Added 137.96%	47,407 $996,000
Q1 2020 May 15, 2020	BUY	$9.44 - $15.58 $19,200 - $31,689	2,034 Added 11.37%	19,922 $244,000
Q4 2019 Feb 14, 2020	SELL	$10.43 - $17.67 $12,255 - $20,762	-1,175 Reduced 6.16%	17,888 $262,000
Q3 2019 Nov 14, 2019	SELL	$13.07 - $18.51 $9,724 - $13,771	-744 Reduced 3.76%	19,063 $254,000
Q2 2019 Aug 14, 2019	SELL	$13.88 - $18.41 $9,369 - $12,426	-675 Reduced 3.3%	19,807 $324,000
Q1 2019 May 15, 2019	BUY	$12.79 - $17.62 $261,964 - $360,892	20,482 New	20,482 $350,000

Others Institutions Holding NTLA

# of Institutions

344

Shares Held

98.4M

Call Options Held

784K

Put Options Held

713K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $727M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account